Nardosinanone N suppresses LPS-induced macrophage activation by modulating the Nrf2 pathway and mPGES-1.

In conclusion, NAN may be a new anti-inflammatory drug that has fewer side effects than NSAIDs and can be a new potential Nrf2 activator and mPGES-1 inhibitor. PMID: 31536727 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31536727?dopt=Abstract

Source: Biochemical Pharmacology - September 15, 2019 Category: Drugs & Pharmacology Authors: Lio CK, Luo JF, Shen XY, Dai Y, Machado J, Xie Y, Yao YD, Yu Y, Liu JX, Yao XS, Luo P, Zhou H Tags: Biochem Pharmacol Source Type: research